EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy of Low‐Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double‐Blind Randomized Clinical Trial

Roghayeh Savary-Kouzehkonan iD, Kourosh Sadeghi iD, Soroush Rad iD, Neda Alijani iD, Zohreh Baseri iD, Mohammad Vaezi iD, Seyed Asadollah Mousavi iD, Bita Shahrami iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70837 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Roghayeh Savary-Kouzehkonan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Fluconazole, Antifungal Agents, Candidiasis, Invasive, Leukemia. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Invasive fungal infections (IFIs), particularly Candida infections, are a significant cause of morbidity and mortality in patients with acute leukemia. While fluconazole is widely used for prophylaxis, the optimal dosing regimen remains uncertain. This study aimed to evaluate the efficacy of low‐dose fluconazole for primary prophylaxis against invasive Candida infections in patients with acute leukemia receiving intensive chemotherapy.

Methods

A double‐blind, randomized clinical trial was conducted with patients diagnosed with acute leukemia. Patients were assigned to receive either low‐dose (150 mg/day) or standard high‐dose (400 mg/day) fluconazole for primary prophylaxis against invasive Candida infections during intensive chemotherapy. The primary outcomes were the efficacy of antifungal prophylaxis and the safety profile.

Results

A total of 120 patients (60 per group) were enrolled. The overall incidence of Candida infections was similar between the groups ( p = 0.615). Candida colonization was higher in the low‐dose fluconazole group during the first week, particularly with non‐albicans Candida at oral and subaxillary sites ( p < 0.001). However, by the third week, both groups showed a significant decline in colonization, with the reduction in the oral cavity being statistically significant ( p = 0.03). Aspergillosis occurred in 38.3% of patients, with no significant difference between groups ( p > 0.99). Adverse events were similar in both groups ( p > 0.05).

Conclusion

Low‐dose fluconazole is an effective alternative to high‐dose regimens for preventing Candida infections in acute leukemia patients, with similar efficacy and safety. The rising threat of aspergillosis highlights the need for targeted prophylaxis. Further research is needed to refine strategies for high‐risk patients. Trial Registration Iranian Registry of Clinical Trials (IRCT) number: IRCT20140818018842N37

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluconazoleAntifungal AgentsCandidiasis, InvasiveLeukemiaLeukemia, Myeloid, AcuteHumansFemaleMaleDouble-Blind MethodMiddle AgedAdultYoung AdultAgedTreatment OutcomeAdolescentCandida

Stichwörter der Autor:innen

Candidaacute leukemiaantifungal prophylaxisfluconazolehematological malignancyinvasive fungal infection

Substanzen

FluconazoleAntifungal Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Hematology, Oncology, and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Infectious Disease, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Roghayeh Savary-Kouzehkonan, Kourosh Sadeghi, Soroush Rad, Neda Alijani, Zohreh Baseri, Mohammad Vaezi, Seyed Asadollah Mousavi, Bita Shahrami

Zitieren

APA

Savary-Kouzehkonan, R., Sadeghi, K., Rad, S., Alijani, N., Baseri, Z., Vaezi, M., Mousavi, S. A., & Shahrami, B. (2025). Efficacy of Low‐Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double‐Blind Randomized Clinical Trial. Cancer Medicine. https://doi.org/10.1002/cam4.70837

Vancouver

Savary-Kouzehkonan R, Sadeghi K, Rad S, Alijani N, Baseri Z, Vaezi M, et al. Efficacy of Low‐Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double‐Blind Randomized Clinical Trial. Cancer Medicine. 2025. doi:10.1002/cam4.70837

BibTeX
@article{SavaryKouzehkonan2025,
  author = {Savary-Kouzehkonan, Roghayeh and Sadeghi, Kourosh and Rad, Soroush and Alijani, Neda and Baseri, Zohreh and Vaezi, Mohammad and Mousavi, Seyed Asadollah and Shahrami, Bita},
  title = {Efficacy of Low‐Dose Fluconazole for Primary Prophylaxis of Invasive Candida Infections in Patients With Acute Leukemia: A Double‐Blind Randomized Clinical Trial},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70837}
}
Kostenlos starten →